Skip to content

The effect of letrozole on endometrial thickness in endometriosis IVF parients

The effect of letrozole on endometrial thickness in endometriosis parients who are candidate for IVF

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20091012002576N26
Enrollment
80
Registered
2022-09-13
Start date
2022-09-22
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Female infertility of other origin

Interventions

Intervention 1: Intervention group: Two tablets of letrozole 2.5 mg(Aboureihan pharmaceutical) will be used from second day of induction ovulation and continued for five days then induction continued

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: IVF Candidate History of endometriosis

Exclusion criteria

Exclusion criteria: pathologic lesion in endometrial cavity pathologic lesion in endometrial cavity; hypersensitivity to letrozole; liver disease liver disease

Design outcomes

Primary

MeasureTime frame
Endometrial thickness. Timepoint: At the day of triggering(5days after ending intervention). Method of measurement: By vaginal ultrasound.

Secondary

MeasureTime frame
Chemical pregnancy. Timepoint: Two weeks after embryo transfer. Method of measurement: BhCG test.;Clinical pregnancy. Timepoint: Four weeks after embryo transfer. Method of measurement: Visualisation fetal heart rate by vaginal ultrasound.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Davari Tanha

Tehran University of Medical Sciences

Fatedavtanha@gmail.com+98 21 8880 0115

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026